The core medical science team - with Sloan Kettering heritage, New York Medical College appointments, Cornell University and NY Presbyterian posts - created the intellectual property behind Capridine and Provax
• They are backstopped by an advisory dream team of prominent Oncologists, Geneticists, Cellular Biologists and Immunologists
• From the Cancer Institute of NJ, BU, Baylor, Merck and Agenus.
Management is supplemented by a team of public company professionals and advisors to guide AVT from its development stage through profitable operations and value growth.
Dr. Mittelman has served as the Company’s Chief Executive Officer, Chief Financial Officer and Chairman since December 13, 2013. Dr. Mittelman, 66, is a practicing Oncologist with an extensive background in theoretical, clinical and practical research experience and a keen ability to identify novel therapeutics as well as the ability to measure their clinical outcome. He is an Associate Professor of Microbiology and Immunology at New York Medical College, a position he has held since 2000. He is also Associate Professor of Medicine, Department of Medicine, New York Medical College (NYMC) (since 1983) and Attending Physician in the Department of Medicine, Division of Oncology, at Westchester Medical Center (since 1983). His academic training as Research Fellow was at Memorial Sloan-Kettering Cancer Center, New York City, in Oncology. He has previously held the position of Assistant Professor of Medicine at Cornell University. Dr. Mittelman has extensive experience in managing clinical trials in investigational pharmaceuticals and immunological agents.
Dr. Mittelman currently serves on the Editorial Board for the publication of Cancer Investigation and Clinics of Oncology and Hematology. He previously served on the Editorial Board of Acta Hematologica. He currently reviews papers for submission to Cancer, The Journal of mmunology, and American Cancer Society. In addition to being an active researcher, Dr. Mittelman is a prolific writer and has authored or co-authored more than 150 scientific papers and book chapters, and more than 200 abstracts. Many of these papers have been presented at international conferences on cancer research.
Dr. Mittelman is the President of the New York State Society of Medical Oncology and Hematology, and is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, the American Society of Pharmacology, and the Society of Biologic Therapy. He has received numerous awards for his clinical research.
Dr. Mittelman holds an MD degree from the University of Guadalajara. He previously studied in the Masters’ Program, majoring in Physics, at New York University. His undergraduate degree is from Pratt Institute. Dr. Mittelman’s medical and scientific knowledge and experience qualify him to serve on the Company’s board of directors.
Mr. Gardner is the founding member of New World Technology Partners (“NWTP”) and has been a leader in “strategic” technology development and an incubator of technology enterprises since the mid-seventies. He has managed and participated in the launch of several development stage companies, including August Systems, Verdix, Meiko Scientific, Cryptek, Phoenix Numeric and Probity Labs. He also led turnarounds of public companies, including General Kinetics and Verdix Corp. At a mid-cap Department of Defense service provider, he created an intellectual property incubator which introduced Trusted TeamWorks™ and several Machine-vision innovations. He recently led the development of the iRISK™ enterprise risk management methodology. Prior to forming NWTP, he held senior engineering and technical marketing positions for Burroughs Corporation’s Supercomputer activities, including ILLIAC IV, PEPE, LDSP and NASF, for which he received both technical and sales accolades and awards. Mr. Gardner has a BSEE from Rensselaer Polytechnic Institute and studied graduate system engineering and business administration at Penn State and the University of Santa Clara respectively. He writes and speaks on topics regarding intellectual property and has prepared briefings and testimony for the U.S. House of Representatives and Senate committees and caucuses.
Dr. Coleman is a medical oncologist who specializes in the treatment of patients with lymphoma, multiple myeloma, leukemia, and Hodgkin’s lymphoma. He shares his expertise through clinical professorships and as a member and chairman of numerous medical and scientific committees. A frequent collaborator on more than 70 research articles, Dr. Coleman is known worldwide for the treatment of lymphoma, myeloma, and leukemia. This includes innovations in dose intensity, treatment combinations, and the sequencing, timing, and duration of chemotherapy. He has received many honors, including annual designation as one of America’s Top Doctors by both Castle Connolly and New York Magazine. He is on the staff of NewYork-Presbyterian/Weill Cornell.
Dr. Tiwari has served as the Company’s Chief Scientific Officer and director since December 13, 2013. Dr. Tiwari, 57 is a Cancer Biologist with over 25 years of cancer research. He is a Professor of Microbiology and Immunology, the Graduate Program Director, and Professor of Otolaryngology at New York Medical College, a position he has held since 1996. An accomplished scientist of international repute, has over 150 publication and abstracts, is a leader in cancer prevention and control and in inventor of several patents involving Capridine and Cancer Vaccine which are part of our intellectual property.
Dr. Tiwari was Assistant Professor of Biochemistry in Surgery, Cornell University Medical College (1991-1996), New York, Assistant Laboratory Member for the Sloan-Kettering Institute for Cancer Research (1989-1991). During the same period he served as Assistant Attending Biochemist for Memorial Hospital, Breast Service. Dr. Tiwari has a Ph.D. in Biochemistry from Calcutta University and received his post-doctoral training at the University of Toronto, Canada (1984-1985) and then at Sloan-Kettering Cancer Institute, New York (1986-1989).
In addition to his academic appointments, Dr. Tiwari reviews grant applications for the American Cancer Society, the American-Italian Foundation, the Dutch Cancer Society, and the Governments of Israel and Italy. He also reviews papers for a number of referred scientific publications that include: Cancer Research, Journal of Clinical Oncology, Anti-Cancer Research, American Journal of Gastroenterology, Journal of the National Cancer Institute, Journal of Interferon Research, Peptides, FASEB Journal, and Breast Cancer Research and Treatment.
Dr. Tiwari has published over one hundred scientific articles, primarily in cancer biology. Dr. Tiwari has been honored a number of times for his scholarship, including: (i) National Scholarship, Government of India (1972-1979); (ii) Junior Research Fellowship, Indian Council of Medical Research (1979-1982); (iii) Senior Research Fellowship, Indian council of Medical Research (1982-1983); (iv) Post-Doctoral Fellowship, University of Toronto (1983-1985); and (v) Post- Doctoral Fellowship, the National Institute of Health (1992). He is the author of several awarded patents.
Dr. Tiwari is a member of the American Association for Cancer Research, the American Association for the Advancement of Science, the Society for Interferon Research, the Harvey Society and the New York Academy of Sciences. Dr. Tiwari is also a member of the Molecular Biology Study Section which reviews and awards grants for breast cancer from the US Army Medical Research Command. His research has been funded by grants from the National Institute of Health (NIH), the US Army Medical Research Command (Breast and Prostate Cancer Initiative), and the American Institute for Cancer Research. Dr. Tiwari’s medical and scientific knowledge and experience qualify him to serve on the Company’s board of directors.
Dr. Geliebter has served as the Company’s Secretary since December 13, 2013. Dr. Geliebter, 58, brings to the Company experience in areas including research of prostate cancer, thyroid cancer, vaccines, and infectious diseases.
Dr. Geliebter is the Professor of Microbiology and Immunology, Associate Professor of Medicine, Associate Professor of Otolaryngology, and Medical Microbiology Course Director at New York Medical College. He joined New York Medical College as Assistant Professor of Microbiology and Immunology in 1996. Previously, Dr. Geliebter was Assistant Professor of Urology at Albert Einstein College of Medicine (1993 – 1996). Prior to this, he held the position of Assistant Investigator for the Howard Hughes Medical Institute (1988 – 1993). During the same period, Dr. Geliebter was an Assistant Professor for The Rockefeller University. In his early graduate career, he served as a Research Associate for Albert Einstein College of Medicine (1984 – 1987) and a Postdoctoral Fellow (1981 – 1984).
In addition to his academic appointments, Dr. Geliebter serves as an Ad hoc Reviewer for the periodicals: Journal of Urology, Cancer Investigation, Cancer, and Peptides . He is very active in a wide range of educational activities at the New York Medical College on the graduate level and the medical school and also has a keen interest in helping high school students considering a career in science.
Dr. Geliebter has published over fifty (50) scientific articles. He has been awarded three (3) patents and currently has two (2) patents pending. Dr. Geliebter has been honored for his scholarship by the American Cancer Society, National Cancer Institute, Albert Einstein College of Medicine, Pfeiffer Foundation, and New York Medical College. Dr. Geliebter holds a PhD in Microbiology and Immunology from SUNY, Downstate Medical Center.
Dr. Geliebter is a member of the American Association for Cancer Research, the American Association for the Advancement of Science, and the New York Academy of Sciences. His research has been funded by grants from the Pfeiffer Foundation, American Institute for Cancer Research, Retirement Research Foundation, Zita Spiss Foundation, Zalmin Arlin Cancer Research Fund, National Institute of Health, and the National Cancer Institute.
Mr. Ronald J. Kovach has had a multifaceted career that spans more than thirty-five (35) years, with one exception, all within the business of health care and medical technology. His career covers: sales and sales training; marketing, market research and advertising; communications including conference promotion, television production, and medical writing; investment banking including private placements, mergers and acquisitions, as well as initial public offerings (IPOs); entrepreneurship; and consulting. His areas of interest are: 1) development and initial implementation of health care related businesses with a specific interest in preparing the business for a public offering; 2) general health care marketing including strategic planning, market research, product and/or service placement and positioning, and advertising; 3) medical writing for specialty medical business journals on the future of medical markets; 4) the biology of aging and the potential for eliminating the debilitating diseases associated with aging; and Universal Design, a school of design that has significant applications for the housing of this country’s aging population.
Mr. Kovach’s current endeavors, besides his involvement with Applied Vaccines Therapeutics, includes: 1) designing Aging in Place townhouses for Bakos Homes, Inc., Jim Thorpe, PA; 2) writing a book with his son, Brett Kovach, PhD. The book is currently titled Building the Perfect Retirement Home; and 3) developing a venture capital fund for a major hospital in Pennsylvania to fund start-ups and development stage companies in the health care technology field(s).
Some of Mr. Kovach’s significant accomplishments follow:
Designed and marketed an Aging in Place development with an association with Steve Bakos Homes, Inc.
Founded and became CEO of a mobile nuclear cardiology company and a mobile ultrasound company, the holding company was called Medical Providers’ Capital Network, Inc.
Produced and moderated a series of videotape presentations on the Safe Harbor Regulations which were complimentary regulations to the Stark Laws. More than 300 sets of the tapes were sold nationally to physicians and their lawyers.
Produced two (2) television shows for the American Medical Association (AMA) on the Stark Laws (I & II) which made it unlawful for physicians to form joint venture arrangement with other physicians to which they would refer their own patients. The two (2) programs were televised over the Discovery Channel in September of 1991.
Senior Vice President in Corporate Finance for Steinberg & Layman, a Wall Street Investment Banking Firm specializing in health care ventures. During his tenure, he was involved in more than twenty (20) merger and acquisition as well as private placement deals. He was also involved in the structuring of more than a dozen initial public offerings (IPOs).
Designed, authored and published the most comprehensive market research study ever attempted on diagnostic testing in physicians’ offices. The final report was almost 2000 pages in length.
Initiated for the Bayer Aspirin line of Sterling Drugs, a program to take an aspirin a day to prevent a heart attack.
Marketing Director and National Sales Manager for Baker Diagnostics. During his tenure, he guided them to an annual average growth rate of thirty-four percent (34%).
Mr. Kovach holds B.S. and M.Sc. Degrees in Biology. He also has completed an extensive array of graduate work focused on medical physiology at Columbia University.